Dako in Diagnostic Alliance with Amgen

Dako has entered into a collaboration with Amgen to develop a diagnostic test for an Amgen cancer drug candidate in clinical development.

“It is Dako’s mission to fight cancer. Hence, we are pleased to be chosen as Amgen’s partner once again for the development of companion diagnostics linked to Amgen’s investigational targeted therapies,” said Lars Holmkvist, Dako’s chief executive officer. “This new collaboration underlines Dako’s commitment to advance personalized medicine in cancer treatment as the selection of patients most likely to benefit from a specific treatment will increase the probability of therapeutic success for cancer patients suffering.”

In January 2012, the two companies entered a collaboration to support the concurrent development of drug and diagnostics for a rare but deadly cancer.